Evidence map›Paper›PMID 39358432›Full record

Trial reportScientific reports2024

Safety and efficacy assessment of fecal microbiota transplantation as an adjunctive treatment for IgA nephropathy: an exploratory clinical trial.

Wenqiang Zhi, Aizhong Li, Qian Wang, Xiaoli Yuan, Jianbo Qing, Caixiang Zhang, Yuxin Wang, Yafeng Li

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wenqiang ZhiThe Nephrology Department of Shanxi Provincial People's Hospital, Shanxi Medical University, Taiyuan, 030001, China.
Aizhong LiThe Nephrology Department of Shanxi Provincial People's Hospital, Shanxi Medical University, Taiyuan, 030001, China.
Qian WangThe Nephrology Department of Shanxi Provincial People's Hospital, Shanxi Medical University, Taiyuan, 030001, China.
Xiaoli YuanThe Nephrology Department of Shanxi Provincial People's Hospital, Shanxi Medical University, Taiyuan, 030001, China.
Jianbo QingThe Nephrology Department of Shanxi Provincial People's Hospital, Shanxi Medical University, Taiyuan, 030001, China.
Caixiang ZhangThe Nephrology Department of Shanxi Provincial People's Hospital, Shanxi Medical University, Taiyuan, 030001, China.
Yuxin WangThe Nephrology Department of Shanxi Provincial People's Hospital, Shanxi Medical University, Taiyuan, 030001, China.
Yafeng LiThe Nephrology Department of Shanxi Provincial People's Hospital, Shanxi Medical University, Taiyuan, 030001, China. Dr.yafengli@gmail.com.

Funding

National Science Foundation of China 82170716
6 · The paper itself

Abstract

To assess the safety and efficacy of fecal microbiota transplantation (FMT) as an adjunctive therapeutic intervention for IgA nephropathy (IgAN). Fifteen patients with IgA nephropathy were recruited based on inclusion and exclusion criteria and underwent FMT using enteric microbial capsules. Clinical indicators, intestinal microbiota and metabolomic profiles, as well as changes in serum immune cells and cytokines, were monitored before and after FMT. No severe adverse reactions were observed in the subjects. After FMT, there was a reduction in the 24-h urinary protein quantification in subjects. The relative abundances of Phocaeicola_vulgatus, Bacteroides_uniformis, Prevotella_copri, Phocaeicola_dorei, Bacteroides_ovatus, Bacteroides_xylanisolvens, Parabacteroides _distasonis, Bifidobacterium_pseudocatenulatum, Bacteroides_sp._HF-162, and Bifidobacterium_longum changed after FMT. In terms of intestinal metabolites, the levels of acylcarnitine18:0 (ACar.18:0), cotinine, N-arachidonoyl-L-serine, phosphatidylcholine (PC. (18:3e/22:6)), serotonin, and fumagillin showed significant changes. Flow cytometry analysis showed the absolute count of plasma B cells decreased in subjects, and this change correlated with alterations in the intestinal microbiota and metabolites. This study preliminarily evaluates the safety and efficacy of FMT in patients with IgAN. No significant adverse reactions were observed, and the administration of FMT alongside ACEI/ARB therapy was effective in reducing urinary protein levels in patients with IgAN, a process that may be associated with B-cell immunity.

Indexed as

Fecal Microbiota TransplantationGastrointestinal MicrobiomeGlomerulonephritis, IGAAdultCytokinesFemaleHumansMaleMiddle AgedTreatment OutcomeCytokinesClinical trialFecal microbiota transplantationGut microbiota and metabolitesIgA nephropathyImmune function

Identifiers

PMID39358432
PMCPMC11446926

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.